SLC35A2 CRISPR/Cas9 KO Plasmid (m): sc-423599
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SLC35A2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SLC35A2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SLC35A2 CRISPR/Cas9 KO Plasmid (m) | sc-423599 | 20 µg | $397.00 |
Overview
Slc35a2 encodes SLC35A2, a Golgi-resident UDP-galactose transporter that imports nucleotide sugar substrates into the secretory pathway to support galactosylation of glycoproteins and glycolipids. By regulating glycan maturation, SLC35A2 influences protein folding, vesicular trafficking, cell–cell adhesion, and receptor signaling, with downstream effects on pathways that depend on proper surface glycosylation. Perturbation of UDP-galactose transport can alter ER/Golgi homeostasis and membrane protein function, impacting processes such as neuronal development and immune cell interactions. Dysregulated glycosylation linked to SLC35A2 has been associated with congenital disorders of glycosylation and broader phenotypes involving neurodevelopmental and epithelial tissue function, making it a relevant target for mechanistic studies in mouse models.
SLC35A2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Slc35a2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Slc35a2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Slc35a2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SLC35A2 protein expression.
This CRISPR knockout system enables efficient generation of Slc35a2-deficient cell models for investigation of SLC35A2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Slc35a2 exon(s) critical for SLC35A2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Slc35a2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SLC35A2 CRISPR/Cas9 KO Plasmid (m) and SLC35A2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Slc35a2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SLC35A2 HDR Plasmid (m) and SLC35A2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Slc35a2 homology arms to support homology-directed repair at defined Slc35a2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.